ICG-Guided Sentinel Lymph Node Mapping for Pediatric Solid Tumors (T-LyM Trial)

This clinical trial investigates the feasibility and safety of using Indocyanine Green (ICG) to map sentinel lymph nodes in children with solid tumors like sarcoma, rhabdomyosarcoma, and germ cell tumors. The study aims to help surgeons more accurately identify cancerous lymph nodes while minimizing unnecessary tissue removal in young patients.

Key aspects of the study:

• Tests a fluorescent dye (ICG) with special imaging equipment during surgery
• Focuses on children under 18 years old with solid tumors
• Seeks to improve lymph node detection without using radioactive tracers
• Enrolls 10 patients at University of Rochester Medical Center

Why this research matters:

Current lymph node mapping techniques for pediatric cancers often rely on radioactive substances or blue dyes that have limitations. ICG fluorescence offers potential advantages:

1. Real-time visualization during surgery
2. No radiation exposure for children
3. Possible higher detection rates of cancerous nodes

The study will measure how often ICG successfully identifies sentinel lymph nodes (primary outcome) and whether these nodes accurately predict cancer spread in the entire lymph node area (secondary outcome). Researchers will monitor patients for any adverse reactions to the ICG dye.

Patient considerations:

This Phase 1 trial represents an important step toward safer surgical approaches for childhood cancers. Pediatric solid tumors present unique challenges due to children's developing bodies and the need to balance effective cancer removal with long-term quality of life. Lymph node assessment plays a crucial role in staging and treatment decisions, making accurate mapping vital.

For families considering participation, the study excludes children with iodide allergies, very small infants (under 650g), or those who had prior surgeries that might affect lymph drainage. The research team will provide detailed information about the procedure's benefits and risks during the consent process.

While the trial focuses on technical feasibility, successful results could lead to larger studies comparing ICG to standard methods. This innovation might eventually reduce surgical complications and improve recovery for children with cancer. The medical community particularly needs better tools for rare pediatric tumors where current lymph node assessment techniques remain suboptimal.

Researchers continue exploring ways to minimize invasive procedures for young cancer patients while maintaining diagnostic accuracy. This trial contributes to broader efforts to tailor cancer surgeries specifically for children's needs, recognizing that their growing bodies require different considerations than adults. The findings may also inform approaches for other cancers where lymph node mapping is crucial for treatment planning.